Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| A532810 | Other Identifier | UW- Madison | |
| Protocol Version 10/1/2024 | Other Identifier | UW - Madison | |
| SMPH/OBGYN BENIGN GYN | Other Identifier | UW - Madison |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn about how the duration of use of The Leva Pelvic Health System® affects treatment of fecal incontinence in women. The main question it aims to answer is to test whether use of the The Leva Pelvic Health System® for 8 weeks is as good as using it for 16 weeks.
Participants will complete surveys, and use the Leva device.
This study will assess whether 8 weeks of use of the Leva Pelvic Health System (Leva) is non-inferior to 16 weeks of use for the treatment of chronic fecal incontinence (symptoms >/= 3 months) in adults with a vagina. Participants will be instructed to complete pelvic floor muscle training using the Leva for 8 or 16 weeks.
The hypothesis is that 8 weeks of use of Leva is non-inferior to 16 weeks of use, assessed by a validated FI symptom severity survey. Surveys will be completed at 0 weeks, 16 weeks, and 24 weeks. Long-term surveys will be completed at 1 year and 2 years from enrollment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 8 week use of Leva | Experimental |
| |
| 16 week use of Leva | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Leva Pelvic Health System | Device | The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
| Measure | Description | Time Frame |
|---|---|---|
| Vaizey Score to Compare Effectiveness of Improving Fecal Incontinence Between 8 Weeks and 16 Weeks of Use | Treatment response as length of use on symptom improvement at 16 weeks (comparing 8 weeks vs 16 weeks of use of Leva) as assessed by Vaizey Score, score ranges from 0-24, higher scores indicate more severe symptoms. A difference of -4.3 ± 3 is expected at 8 weeks and 16 weeks (compared to baseline), with an allowable difference of 1. | Baseline to 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Fecal Incontinence Severity | Using St. Mark's Incontinence score, score ranges from 0-24, higher scores indicate more severe symptoms. | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years |
| Cumulative Adherence Correlation With Change in St. Mark's Score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dobie Giles, MD | University of Wisconsin, Madison | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Wisconsin | Madison | Wisconsin | 53705 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 8 Week Use of Leva | The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
| FG001 | 16 Week Use of Leva | The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 8 Week Use of Leva | The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
| BG001 | 16 Week Use of Leva |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Vaizey Score to Compare Effectiveness of Improving Fecal Incontinence Between 8 Weeks and 16 Weeks of Use | Treatment response as length of use on symptom improvement at 16 weeks (comparing 8 weeks vs 16 weeks of use of Leva) as assessed by Vaizey Score, score ranges from 0-24, higher scores indicate more severe symptoms. A difference of -4.3 ± 3 is expected at 8 weeks and 16 weeks (compared to baseline), with an allowable difference of 1. | one participant withdrew, one participant was lost to follow up at 16 weeks | Posted | Mean | Standard Deviation | score on a scale | Baseline to 16 weeks |
|
up to 16 weeks (for primary outcome at the time of reporting)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 8 Week Use of Leva | The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Sciatic Pain | Nervous system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ushma Patel, MD | UW School of Medicine and Public Health | (608) 287-5898 | upatel@uwhealth.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 23, 2025 | May 12, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D005242 | Fecal Incontinence |
| D004688 | Encopresis |
| ID | Term |
|---|---|
| D012002 | Rectal Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Adherence as a percentage of all expected exercise sessions correlated with change in St Mark's Incontinence Score (1-24) |
| Baseline to 24 weeks, long term follow up at 1 and 2 years |
| Patient Satisfaction and Usability of the Smartphone Application Component of the Leva Pelvic Health System | Measured through the mHealth App Usability Questionnaire. In this questionnaire, 1 - strongly disagree, 2 - disagree, 3 - somewhat disagree, 4 - neither agree nor disagree, 5 - somewhat agree, 6 - agree, 7 - strongly agree. To determine the usability of an app, calculate the total and determine the average of the responses to all statements. The higher the overall average, the higher the usability of the app. | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years |
| Change in Fecal Incontinence From Baseline to 24 Weeks After 8 or 16 Weeks of Treatment | Treatment response as length of use on symptom improvement at 24 weeks (comparing 8 weeks vs 16 weeks of use of Leva) as assessed by St Mark's (Vaizey) scores. | Baseline to 24 weeks, long term follow up at 1 and 2 years |
| Change in Pelvic Organ Prolapse Quantification System (POP-Q) | The POP-Q system is an objective, site-specific system used to describe, quantify, and stage pelvic support. Measurements are rated as Stage 0-Stage 4, with Stage 4 being complete prolapse. | Baseline to 16 weeks |
| Change in Brink Scale Score: Pressure | The Brink scale evaluates 3 PFM contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner's fingers, and duration of contraction. Each muscle contraction variable is rated on a 4-point ordinal scale (1-4). Higher scores indicating greater strength. | Baseline to 16 weeks |
| Change in Brink Scale Score: Vertical Displacement | The Brink scale evaluates 3 PFM contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner's fingers, and duration of contraction. Each muscle contraction variable is rated on a 4-point ordinal scale (1-4). Higher scores indicating greater strength. | Baseline to 16 weeks |
| Change in Brink Scale Score: Duration Contraction | The Brink scale evaluates 3 PFM contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner's fingers, and duration of contraction. Each muscle contraction variable is rated on a 4-point ordinal scale (1-4). Higher scores indicating greater strength. | Baseline to 16 weeks |
| Change in Stool Consistency | Use the Bristol Stool Scale to evaluate stool consistency. Ranges from Type 1 to Type 7, where Type 1 is hardest consistency and Type 7 is entirely liquid. | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years |
| Change in Fecal Incontinence Quality of Life (FIQoL) | Use FIQoL scale, in which participants rate questions about how often an issue is a concern, and how much they agree with statements on a scale of 1-5. Higher scores indicate lower quality of life. | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years |
| Change in Sexual Function (PISQ-IR) | PISQ-IR is a 20 item survey, where higher scores indicate lower sexual function. | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years |
| Patient Global Impression of Improvement (PGI-I) | PGI-I is a 2 question qualitative survey in which participants state their satisfaction and perception of improvement. | 16 and 24 weeks, long term follow up at 1 and 2 years |
| Patient Satisfaction (PGI-I) | PGI-I is a 2 question qualitative survey in which participants state their satisfaction and perception of improvement. | 16 and 24 weeks, long term follow up at 1 and 2 years |
| Estimated Percentage of Change | Qualitative question in which participants state their estimate of how much better they are, on a scale from 0% (no better) to 100% (completely better). | 16 and 24 weeks, long term follow up at 1 and 2 years |
| Change in Global Pelvic Floor Symptoms | Use the Pelvic Floor Distress Inventory (PFDI-20) to evaluate change in pelvic floor symptoms. It is a 20 item survey with a range from 0-100 where higher scores indicate greater symptoms. | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years |
| Evaluate Self-continuation of Pelvic Floor Muscle Exercises | Participant self-report on whether and how often they continued the pelvic floor muscle exercises. | Baseline and 24 weeks, long term follow up at 1 and 2 years |
| Number of Cumulative Adverse Events | Systematic assessment of all adverse events over the course of the study, reported as a number of total AEs. | Baseline and 24 weeks, long term follow up at 1 and 2 years |
| mHealth App Usability Questionnaire (MAUQ) | MAUQ is an 18-item survey scored on a 7 point likert scale from 1 (disagree) to 7 (agree) with higher scores indicative of higher usability. | 16 weeks |
| On Follow Up |
|
The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Brinks Score | Brink Scale measures pelvic floor muscle strength, scored from 1-4 in 3 areas:
| Median | Inter-Quartile Range | units on a scale |
|
| Body Mass Index (BMI) | Mean | Standard Deviation | kg/m^2 |
|
| Pelvic Organ Prolapse (POP-Q) |
| Count of Participants | Participants |
|
| Vaisey Score | A measure of incontinence scored from 0 (perfect continence) to 24 (totally incontinent) | Mean | Standard Deviation | units on a scale |
|
| Bristol Stool Scale | Description of stool between 1-7
| Count of Participants | Participants |
|
| OG001 | 16 Week Use of Leva | The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. |
|
|
|
| Secondary | Change in Fecal Incontinence Severity | Using St. Mark's Incontinence score, score ranges from 0-24, higher scores indicate more severe symptoms. | Not Posted | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Cumulative Adherence Correlation With Change in St. Mark's Score | Adherence as a percentage of all expected exercise sessions correlated with change in St Mark's Incontinence Score (1-24) | Not Posted | Baseline to 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Patient Satisfaction and Usability of the Smartphone Application Component of the Leva Pelvic Health System | Measured through the mHealth App Usability Questionnaire. In this questionnaire, 1 - strongly disagree, 2 - disagree, 3 - somewhat disagree, 4 - neither agree nor disagree, 5 - somewhat agree, 6 - agree, 7 - strongly agree. To determine the usability of an app, calculate the total and determine the average of the responses to all statements. The higher the overall average, the higher the usability of the app. | Not Posted | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Change in Fecal Incontinence From Baseline to 24 Weeks After 8 or 16 Weeks of Treatment | Treatment response as length of use on symptom improvement at 24 weeks (comparing 8 weeks vs 16 weeks of use of Leva) as assessed by St Mark's (Vaizey) scores. | Not Posted | Baseline to 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Change in Pelvic Organ Prolapse Quantification System (POP-Q) | The POP-Q system is an objective, site-specific system used to describe, quantify, and stage pelvic support. Measurements are rated as Stage 0-Stage 4, with Stage 4 being complete prolapse. | one participant withdrew, one participant was lost to follow up at 16 weeks, one participant completed 16-week surveys but did not follow up for in person visit | Posted | Count of Participants | Participants | Baseline to 16 weeks |
|
|
|
|
| Secondary | Change in Brink Scale Score: Pressure | The Brink scale evaluates 3 PFM contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner's fingers, and duration of contraction. Each muscle contraction variable is rated on a 4-point ordinal scale (1-4). Higher scores indicating greater strength. | one participant withdrew, one participant was lost to follow up at 16 weeks, one participant completed 16-week surveys but did not follow up for in person visit | Posted | Median | Inter-Quartile Range | score on a scale | Baseline to 16 weeks |
|
|
|
|
| Secondary | Change in Brink Scale Score: Vertical Displacement | The Brink scale evaluates 3 PFM contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner's fingers, and duration of contraction. Each muscle contraction variable is rated on a 4-point ordinal scale (1-4). Higher scores indicating greater strength. | one participant withdrew, one participant was lost to follow up at 16 weeks, one participant completed 16-week surveys but did not follow up for in person visit | Posted | Median | Inter-Quartile Range | score on a scale | Baseline to 16 weeks |
|
|
|
|
| Secondary | Change in Brink Scale Score: Duration Contraction | The Brink scale evaluates 3 PFM contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner's fingers, and duration of contraction. Each muscle contraction variable is rated on a 4-point ordinal scale (1-4). Higher scores indicating greater strength. | one participant withdrew, one participant was lost to follow up at 16 weeks, one participant completed 16-week surveys but did not follow up for in person visit | Posted | Median | Inter-Quartile Range | score on a scale | Baseline to 16 weeks |
|
|
|
|
| Secondary | Change in Stool Consistency | Use the Bristol Stool Scale to evaluate stool consistency. Ranges from Type 1 to Type 7, where Type 1 is hardest consistency and Type 7 is entirely liquid. | Not Posted | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Change in Fecal Incontinence Quality of Life (FIQoL) | Use FIQoL scale, in which participants rate questions about how often an issue is a concern, and how much they agree with statements on a scale of 1-5. Higher scores indicate lower quality of life. | Not Posted | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Change in Sexual Function (PISQ-IR) | PISQ-IR is a 20 item survey, where higher scores indicate lower sexual function. | Not Posted | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Patient Global Impression of Improvement (PGI-I) | PGI-I is a 2 question qualitative survey in which participants state their satisfaction and perception of improvement. | Not Posted | 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Patient Satisfaction (PGI-I) | PGI-I is a 2 question qualitative survey in which participants state their satisfaction and perception of improvement. | Not Posted | 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Estimated Percentage of Change | Qualitative question in which participants state their estimate of how much better they are, on a scale from 0% (no better) to 100% (completely better). | Not Posted | 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Change in Global Pelvic Floor Symptoms | Use the Pelvic Floor Distress Inventory (PFDI-20) to evaluate change in pelvic floor symptoms. It is a 20 item survey with a range from 0-100 where higher scores indicate greater symptoms. | Not Posted | Baseline to 16 and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Evaluate Self-continuation of Pelvic Floor Muscle Exercises | Participant self-report on whether and how often they continued the pelvic floor muscle exercises. | Not Posted | Baseline and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | Number of Cumulative Adverse Events | Systematic assessment of all adverse events over the course of the study, reported as a number of total AEs. | Not Posted | Baseline and 24 weeks, long term follow up at 1 and 2 years | Participants |
| Secondary | mHealth App Usability Questionnaire (MAUQ) | MAUQ is an 18-item survey scored on a 7 point likert scale from 1 (disagree) to 7 (agree) with higher scores indicative of higher usability. | Posted | Median | Inter-Quartile Range | score on a scale | 16 weeks |
|
|
|
|
| 0 |
| 19 |
| 0 |
| 19 |
| 2 |
| 19 |
| EG001 | 16 Week Use of Leva | The Leva Pelvic Health System: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage. | 0 | 19 | 0 | 19 | 0 | 19 |
| Pelvic Pain with Urination | Renal and urinary disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D019960 | Elimination Disorders |
| D001523 | Mental Disorders |
| Stage 2 |
|
| Stage 3 |
|
| 16 weeks |
|
|
| change from baseline | t-test, 2 sided | continuous outcome | 0.317 | a priori threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
| 16 weeks |
|
|
| change from baseline in Brink Score: Pressure | t-test, 2 sided | continuous outcome | <0.001 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
| 16 weeks |
|
|
| change from baseline in Brink Score: Vertical Displacement | t-test, 2 sided | continuous outcome | <0.001 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
| 16 weeks |
|
|
| change from baseline in Brink Score: Duration Contraction | t-test, 2 sided | continuous outcome | <0.001 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
|
| Q11. I would use this app again |
|
| Q12. Overall, I am satisfied with this app |
|
| Q15. The app helped me manage my health effectively |
|
| Q2. It was easy for me to learn to use the app | t-test, 2 sided | continuous outcome | 0.063 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
| Q11. I would use this app again | t-test, 2 sided | continuous outcome | 0.587 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
| Q12. Overall, I am satisfied with this app | t-test, 2 sided | continuous outcome | 0.107 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |
| Q15. The app helped me manage my health effectively | t-test, 2 sided | continuous outcome | 0.486 | a prior threshold 0.05 | Equivalence | Power analysis was determined based on a 3 point improvement on the Vaizey score in both groups. With an allowable difference of 1 point between randomized groups, type I error level = 0.05, power = 0.8, and standard deviation of outcome of 4. |